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Abstract
Background. Recent work suggests that antihypertensive medications may be useful as repur-
posed treatments for mood disorders. Using large-scale linked healthcare data we investigated
whether certain classes of antihypertensive, such as angiotensin antagonists (AAs) and cal-
cium channel blockers, were associated with reduced risk of new-onset major depressive dis-
order (MDD) or bipolar disorder (BD).
Method. Two cohorts of patients treated with antihypertensives were identified from Scottish
prescribing (2009–2016) and hospital admission (1981–2016) records. Eligibility for cohort
membership was determined by a receipt of a minimum of four prescriptions for antihyper-
tensives within a 12-month window. One treatment cohort (n = 538 730) included patients
with no previous history of mood disorder, whereas the other (n = 262 278) included those
who did. Both cohorts were matched by age, sex and area deprivation to untreated compara-
tors. Associations between antihypertensive treatment and new-onset MDD or bipolar epi-
sodes were investigated using Cox regression.
Results. For patients without a history of mood disorder, antihypertensives were associated with
increased risk of new-onset MDD. For AA monotherapy, the hazard ratio (HR) for new-onset
MDD was 1.17 (95% CI 1.04–1.31). Beta blockers’ association was stronger (HR 2.68; 95% CI
2.45–2.92), possibly indicating pre-existing anxiety. Some classes of antihypertensive were asso-
ciated with protection against BD, particularly AAs (HR 0.46; 95% CI 0.30–0.70). For patients
with a past history of mood disorders, all classes of antihypertensives were associated with
increased risk of future episodes of MDD.
Conclusions. There was no evidence that antihypertensive medications prevented new epi-
sodes of MDD but AAs may represent a novel treatment avenue for BD.
Introduction
Major depressive disorder (MDD) and bipolar disorder (BD) are leading causes of disability
globally (Ferrari et al., 2016; Vos et al., 2016). More than one third of MDD patients will
not respond to first-line antidepressants (Linde et al., 2015) and BD is challenging to treat,
with antidepressants ineffective for most patients (Sidor & Macqueen, 2011). In recent years
there has been little progress in the development of new medications for mood disorders (except
perhaps for ketamine in depression; Krystal, Abdallah, Sanacora, Charney, & Duman, 2019) but
there is currently considerable interest in the possibility of repurposing medications from other
areas of medicine. Specifically, it has been suggested that certain classes of antihypertensive
medication (particularly calcium-channel blockers, CCBs and angiotensin antagonists, AAs)
may have a role as repurposed treatments for MDD or BD (Harrison et al., 2016; Harrison,
Tunbridge, Dolphin, & Hall, 2019; Saavedra, 2017; Vian et al., 2017).
To date, the evidence for repurposing antihypertensive drugs to treat MDD is limited
(Chowdhury, Berk, Nelson, Wing, & Reid, 2019; Vian et al., 2017). AAs have been reported
in small observational studies to be associated with better mental health outcomes (Ahola,
Harjutsalo, Forsblom, & Groop, 2014; Boal et al., 2016; Brownstein et al., 2018; Johansen,
Holmen, Stewart, & Bjerkeset, 2012; Nasr, Crayton, Agarwal, Wendt, & Kora, 2011;
Williams et al., 2016). However, a recent large linkage study found that although initial pre-
scriptions for AAs were associated with increased risk of depression and BD, people receiving
longer-term prescriptions for AAs were not at increased risk (Kessing et al., 2019a, 2019b).
Since the 1980s, CCBs such as verapamil have been suggested as possible treatments for
mania (Celano et al., 2011). This was not supported by a review of six double-blind rando-
mised studies and 17 observational studies which found that no evidence for efficacy of
CCBs in mania (Cipriani et al., 2016). Nonetheless, despite the relatively limited evidence
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base to date, CCBs remain candidates for repurposing in BD
because of their biological plausibility (Cipriani et al., 2016).
There is very little published work supporting the repurposing
of other antihypertensive drug classes for MDD or BD. Case
reports and some clinical trials have found that beta-blockers
(BB) (particularly propranolol) may be associated with increased
depressive features (Luijendijk & Koolman, 2012; Verbeek, van
Riezen, de Boer, van Melle, & de Jonge, 2011) (although recent
observational work suggests that BBs have little influence on
mood disorder outcomes; Boal et al., 2016; Johansen et al.,
2012; Ko et al., 2002; Luijendijk & Koolman, 2012; Nasr et al.,
2011; Ranchord, Spertus, Buchanan, Gosch, & Chan, 2016;
Verbeek et al., 2011). It is possible that depressogenic effects are
restricted to more lipophilic BB (such as propranolol) which
cross the blood–brain barrier (Thiessen, Wallace, Blackburn,
Wilson, & Bergman, 1990; Verbeek et al., 2011). For other antihy-
pertensive drugs, such as diuretics and centrally acting agents,
almost no evidence of any influence on mood disorder outcomes
has so far been described (Celano et al., 2011; Coyne, Davis,
French, & Hill, 2002; Hayes et al., 2019; Huffman & Stern,
2007; Nasr et al., 2011; Williams et al., 2016).
Our primary goal was to use Scottish national-level routine
healthcare data on over 1.8 million individuals (representing
more than 6 million person-years of follow-up) to assess whether
patients treated with specific classes of antihypertensive medica-
tion as monotherapy were less likely to experience new-onset
mood disorder episodes.
Methods
Data sources
Within the National Services Scotland Safehaven, we created two
datasets of cohorts and comparison groups by linking data from:
the Community Health Index; Scottish Morbidity Records (SMR)
datasets including SMR00 (Outpatient Attendance) from 1997 to
2016, SMR01 (General/Acute Inpatient and Day Case) from 1981
to 2016, and SMR04 (Mental Health Inpatient and Day Cases)
from 1981 to 2016; the Prescribing Information System (PIS)
from 2009 to 2016 and the National Records of Scotland death
certificates from 1981 to 2016. Cohort 1 included patients treated
with new-onset antihypertensive treatment (defined below) who
had no previous record of mood disorder. Cohort 2 included
patients with new-onset antihypertensive treatment plus a past
record of mood disorder. Ethical approval for the project was
obtained from the Public Benefit and Privacy Panel at National
Health Services Scotland Information and Statistics division.
Time periods in which potential participants were eligible for
inclusion were defined on the basis of prescriptions for antihyper-
tensive medications, as well as prescriptions and hospital admis-
sion records for psychiatric disorders. To define the cohorts, we
initially used PIS data from January 2009 to December 2016 to
identify individuals who had a minimum of 4 prescriptions for
antihypertensives (defined using British National Formulary
(BNF) (Joint Formulary Committee, 2019) sections and para-
graphs 2.2, 2.4, 2.5.5 and 2.6.2, see online supplementary
Table S1 for more details on the BNF classifications) within a
window of up to 12 months, preceded by 6 months of no antihy-
pertensive treatment record. We used receiving a minimum of
four or more prescriptions from a single antihypertensive treat-
ment as an inclusion criterion because typically a single prescrip-
tion would cover a period of 3 months so a minimum of four
prescriptions would be required to cover a period of 1 year. The
6 months without antihypertensive treatment were to ensure
that subsequent antihypertensive prescriptions were for a new
treatment, rather than part of an ongoing treatment regime.
Patients were then excluded from cohort 1 and included in cohort
2 if they had been prescribed psychiatric medication (indicated by
BNF sections 4.1, 4.2 and 4.3) within the same window. Following
that, we also excluded people from cohort 1 and included them in
cohort 2 if they had been admitted to hospital for psychiatric
treatment (as indicated by a clinic appointment with the general
psychiatry speciality in SMR00 database, ICD10 codes F10–F48,
X60–X84 and Z91.5 and ICD9 codes 290–301 and 303–305 in
the SMR01 database and a record in the SMR04 databases) during
the antihypertensive treatment window and for the preceding 10
years. At this stage, the number of potential cohort 1 members
was 968 930 for cohort 1 (see online supplementary Fig. S1),
and for potential cohort 2 members this number was 555 975
(see online supplementary Fig. S2).
Given that the pool of people for the comparison group was
limited, for both cohorts we selected individuals who had an eli-
gible period that ended after 31/12/2009. We aimed to match
cohort members with comparisons using a 1:1 ratio for cohort
1 and 1:2 for cohort 2. Comparisons for each cohort were initially
selected on the criteria that they had received no antihypertensive
medication between 2009 and 2016, and then on the same criteria
as their corresponding cohort with respect to psychiatric treat-
ment. Matching was on the basis of age (+/− 2 years), sex and
Scottish index of multiple deprivation. Subsequently, cohort-
comparison pairs were excluded from analysis if they either had
a death record prior to the end of their eligible treatment window,
or were outside the age range of 18 to 100. This resulted in
538 789 cohort-comparison pairs for cohort 1, and 272 278 cohort
2 members matched to 502 937 comparators. Descriptive statistics
for unmatched but otherwise eligible patients are shown in online
supplementary file Table S2 for Cohort 1 and online
Supplementary Table S3 for Cohort 2. The main barrier to match-
ing cohort members was age, with it being much harder to find
matches for older cohort members particularly for cohort 2 for
which we used a higher matching ratio.
Antihypertensive monotherapy and polytherapy status
Participants were identified for treatment on the basis of prescrib-
ing records for antihypertensive medication within the 2009–2016
PIS dataset. These codes were then used to classify participants
into specific classes on the basis of the prescription of thiazide
diuretics, BB, AAs (including angiotensin-converting enzyme
(ACE)-inhibitors, angiotensin receptor blockers (ARB) and
renin inhibitors) and CCBs. Patients were included in antihyper-
tensive monotherapy groups if during the 12 months prior to the
end date of the eligibility period they received four or more pre-
scriptions from a single class of antihypertensive treatment and
no prescriptions for any of the other classes. For the analysis of
monotherapy, individuals were subsequently censored at the
date on which they received a prescription for an antihypertensive
drug outside their monotherapy class. Patients were considered to
be on polytherapy if during the last 3 months of the eligible treat-
ment window they received antihypertensive medication from
two or more of thiazide diuretics, BBs, AA or CCBs. Remaining
study participants who had received at least four antihypertensive
treatments but were not eligible for the monotherapy or polyther-
apy groups were classified as ‘other antihypertensive’. See online
2 Richard J. Shaw et al.
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Table S4 in the supplementary file for the frequency of each of the
different combinations.
Outcome measures
We had two outcome measures indicating new-onset of treatment
for episodes of either MDD or BD, indicated by receipt of medi-
cations (PIS) or psychiatric admissions (SMR04) subsequent to
the end date of the eligibility window used to define the cohorts.
Using PIS data, new onset of treatment for MDD was identified
by the prescription of any antidepressant drugs (BNF section
4.3), and new onset of BD was identified by a prescription for
antipsychotics and drugs used for mania and hypomania (BNF
section 4.2). Similarly, the ‘main’ and ‘other diagnoses’ fields in
SMR04 were used to identify first episodes for treatment for
MDD or BD (ICD10 codes F32 and F33 used to indicate MDD
and ICD10 codes F30 and F31 used to indicate BD).
Confounding variables
Medical comorbidities for study members were defined by having
ever received specific prescriptions or attended hospital for spe-
cific conditions as indicated in available PIS, SMR00, SMR01
and SMR04 records, up to end date of the eligibility window.
Using PIS data, ever prescribed cardiovascular medication
(other than antihypertensives) was defined using prescriptions
for drugs from BNF sections or paragraphs 2.1, 2.3, 2.6.1, 2.6.3,
2.6.4, 2.9 and 2.12, and treatment for diabetes was indicated by
receipt of prescriptions of antidiabetic medications (BNF chapter
6.1.2.)
Confounding variables were derived from hospital records
based on specific ICD10 and ICD9 codes, as indicated in the
‘main’ and ‘other conditions’ for SMR00, SMR01 and SMR04
and ‘main’ admission and ‘other’ admission condition for
SMR04. History of cardiovascular disease was defined using
ICD10 codes I20–I25 (ischaemic heart diseases), and I60–I69
(cerebrovascular diseases), and ICD9 codes 410–414 (acute myo-
cardial infarction) and 430–438 (cerebrovascular diseases). Head
injuries were identified using ICD 10 codes S02.0, S02.1, S02.7,
S06, S07 and ICD9 codes 800–804 and 850–854. Substance
abuse was identified using ICD codes F10 to F19, and ICD9
codes 291, 292, 303 to 305. Self-harm was identified using ICD
codes X60–X84 and Z91.5 and ICD 9 codes E950–E958.
Additional confounding variables were defined for cohort 2
who had a history mental illness or mood disorders. PIS data
was used to identify people who had been prescribed the follow-
ing types of pharmaceutical treatment: hypnotics or anxiolytics
(BNF Section 4.1), antidepressants (BNF Section 4.3), or drugs
used in psychoses and related disorders (BNF Section 4.2).
Hospital admission records were used to identify people who
had been admitted to hospital for the following conditions:
Schizophrenia and delusional disorders (ICD10 codes F10–F19
and ICD9 codes 291–292 and 303–305), MDD (ICD10 codes
F32–F33, and ICD9 codes 296.2–296.3), BD (ICD10 codes
F30–F32, and ICD9 codes 296.0, 296.1 and 296.9) and personality
disorders (ICD10 codes F60–F69, and ICD9 code 301).
Data analysis
All analyses were carried out within the National Safehaven using
Stata 14.0 MP. The curves for first onset of mood disorder by
therapy classes are presented using cumulative distributive
functions, which are calculated as 100 percent minus the
Kaplan–Meier estimate (Cleves, Gould, & Marchenko, 2016).
Data were analysed using Cox proportional hazards models,
which were stratified by cohort and control pairs, to investigate
the relationship between specific therapy classes and new-onset
of MDD or BD following the end of the 12 month eligibility win-
dow, after adjustment for age and the other medication and hos-
pital admission variables. Preliminary analyses suggested that the
proportional hazards assumption was violated; consequently this
was addressed using a Heaviside function (Kleinbaum & Klein,
2010) with separate hazard ratios (HRs) calculated for the specific
therapy classes for the following five time periods: 0 to 3 months,
>3 to 6 months, >6 to 12 months, >1 year to 2 years and >2 years.
Results
Sociodemographic characteristics for cohort 1 are shown in
Table 1, and a comparison of both cohorts is shown in online
Supplementary Table S5. The mean age of the different antihyper-
tensive treatment groups varied, with patients on BBs having the
youngest mean age of 53.4 years, while those in the ‘other antihy-
pertensive’ group had the oldest mean age of 66.6 years. Patients
receiving thiazide diuretics, BBs and other patterns of antihyper-
tensive treatments were more likely to be women, while those
receiving AAs, CCBs and polytherapy were more likely to be
men. There were small differences between the groups in terms
of area deprivation, with patients receiving thiazides the most
affluent and those on other medications the least affluent.
Medical history and mood disorder outcomes are also shown
in Table 1 for cohort 1 and in online Supplementary Table S6
for cohort 2. As might be expected for the comparison group,
both the percentages of people having been admitted to hospital
for cardiovascular disease and receiving prescriptions for other
cardiovascular medicines were lower than the equivalent figures
for all the antihypertensive treatment groups. However, for the
other medical history measures the comparison groups fell within
the range of the antihypertensive treatment groups.
Cumulative distribution functions
The cumulative distribution functions for new-onset of an epi-
sode of MDD by therapy class are shown in Fig. 1a for cohort
1 (see online Supplementary Fig. S3a for cohort 2). Numbers at
risk and number of failures for both the treatment cohorts are
shown in online Supplementary Table S7. The main difference
between the two cohorts was the expected higher incidence
rates of MDD episodes in the first 0–3 months for cohort 2,
reflecting that (by definition) these patients already had a record
of mood disorder. The comparison groups for both cohorts had
the lowest risk of receiving treatment for MDD throughout the
follow-up period, and patients receiving BB monotherapy had
the highest risk for MDD episodes. The curve for the ‘other anti-
hypertensive’ treatment group in cohort 1 was similar to the curve
for those receiving BBs in that cohort. Among all the antihyper-
tensive monotherapy groups, those receiving AAs had the lowest
risk of new-onset MDD.
The cumulative distribution functions for new-onset BD epi-
sodes by the antihypertensive monotherapy group are shown in
Fig. 1b. The equivalent figure for cohort 2 is shown in online
Supplementary Fig. S3b. For cohort 1, the ‘other antihypertensive’
group was more likely to receive treatment for new-onset BD
compared to all the other classes of treatment. The comparison
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Table 1. Sociodemographic, medical event and history variables Cohort 1
Comparison
Thiazide diuretics
(thiazide) BB AAs CCBs
Polytherapy
(Poly)
Other
antihypertensives
n % n % n % n % n % n % n %
538 730 100 25 555 100 73 996 100 130 110 100 57 986 100 211 282 100 39 801 100
Gender
Male 285 329 53.0 7612 29.8 32 673 44.2 78 459 60.3 31 135 53.7 119 171 56.4 16 279 40.9
Female 253 401 47.0 17 943 70.2 41 323 55.8 51 651 39.7 26 851 46.3 92 111 43.6 23 522 59.1
Survival events
Treatment for depression 94 073 17.5 6169 24.1 19 181 25.9 25 461 19.6 9752 16.8 46 720 22.1 9321 23.4
Treatment for BD 11 822 2.2 688 2.7 1251 1.7 1816 1.4 1143 2.0 4341 2.1 1753 4.4
Died 41 319 7.7 2211 8.7 4177 5.6 6615 5.1 4092 7.1 17 767 8.9 8785 22.1
Changed therapy na 11 580 45.3 14 701 19.9 43 787 33.6 18 561 32.0 na na
History of hospital treatment measure
Cardiovascular disease 11 523 2.1 1149 4.5 10 293 13.9 9452 7.3 4358 7.5 44 495 21.1 6209 15.6
Substance abuse 6995 1.3 237 0.9 957 1.3 1650 1.3 806 1.4 2822 1.3 583 1.5
Head injury 15 570 2.9 410 1.6 2185 3.0 4054 3.1 1374 2.4 4794 2.3 1003 2.5
Self-harm 1373 0.3 48 0.2 317 0.4 421 0.3 155 0.3 471 0.2 130 0.3
History of prescriptions
Other cardiovascular drugs 61 154 11.4 10 009 39.2 29 355 39.7 59 563 45.8 25 688 44.3 127 965 60.6 19 235 48.3
Diabetic drugs 8372 1.6 854 3.3 2365 3.2 20 027 15.4 2242 3.9 23 359 11.1 2902 7.3
Age
Mean 59.4 64.9 53.4 56.3 63.9 61.2 66.6
S.D. 13.2 11.4 16.6 12.0 11.9 11.2 15.5
SIMD 2016
Mean 5.6 5.8 5.6 5.7 5.7 5.6 5.5
S.D. 2.8 2.8 2.8 2.8 2.8 2.8 2.8
‘Other Antihypertensives’ were defined on the basis of treatment with a combination of thiazide diuretics, diuretics, BBs, AA and/or CCBs, but not treatment with at least two of these groups within in the last 3 months of the eligible treatment window.
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group curve lay between the curves for the other antihypertensive
classes, and people receiving polytherapy and AAs were somewhat
less likely to be treated for BD than the other therapy classes.
Once the (expected) sharp incidence rate is accounted for in
cohort 2, curves were similar to cohort 1.
Cox proportional hazard models for new-onset of depression
The HRs (after adjustment for hospital treatment for cardiovascu-
lar disease, substance abuse, head injury, self-harm and pharma-
ceutical treatment for other cardiovascular or diabetic drugs) for
the relationship between receiving a specific class of antihyperten-
sive and new-onset MDD over time for people without a prior
history of mood disorder (cohort 1) are shown in Fig. 2.
For people receiving most monotherapy treatments and the
polytherapy group there was a small but consistently elevated
HR of around 1.2, which declined with time. For people receiving
‘other antihypertensive’ treatments, there was a slightly higher HR
of around 1.5 for all time points. In contrast, the HR for people
treated with BBs was initially high at 2.68 (95% CI 2.45–2.92)
in the first 3 months, before declining to 2.01 (95% CI 1.88–
2.13) after 6 months and 1.44 (95% CI 1.38–1.50) at 2 years.
We explored the possibility that any associations were
restricted to sub-groups among AAs and BBs. During the first 3
months the HR for participants being treated with propranolol
(N = 30 478) was 4.80 (95% CI 4.22–5.46), with this falling over
time (3 to 6 months: HR 3.74, 95% CI 3.31–4.23, 6 to 12 months:
HR 3.29, 95% CI 2.99–3.62, 1 to 2 years: HR 2.73, 95% CI 2.51–
2.97) to just 2.04 (95% CI 1.91–2.17) after 2 years. In contrast, the
associations for atenolol (n = 16 650), other BB (N = 26 868) and
the two subclasses of AAs (ACE inhibitors, N = 105 064, or
ARB, N = 16 071) were consistently weak, with a HR of around
1.1. We also ran additional analyses separately for men (online
Supplementary Fig. S4) and women (online Supplementary
Fig. S5). The odds ratios for new-onset depression for nearly all
antihypertensive classes were larger for women than the corre-
sponding odds ratios for men, however, the gender differences
were small and conclusions drawn for both genders are similar.
There was greater consistency of relationships between all ther-
apy classes of antihypertensive treatment and new-onset MDD
episodes for people with a prior history of mood disorder (cohort
2; online Supplementary Fig. S6). For most antihypertensive
groups, the HRs were around 1.4 at 0–3 months and about 3
for between 3–6 months, with HRs continuing to increase there-
after. However, BBs appeared to have a slightly stronger associ-
ation at 0 to 3 months (HR 1.93, 95% CI 1.90–1.96) and at 3 to
6 months (HR 3.83, 95% CI 3.63–3.04). Further analyses indicated
that elevated HRs for people on BBs were restricted to people who
had been prescribed propranolol.
Cox proportional hazard models for new-onset bipolar
disorder
In adjusted analyses for people with no previous history of mood
disorder (cohort 1), most therapy classes of antihypertensive
drugs were initially associated with reduced risk of BD episodes,
with the risk subsequently increasing towards a null association
over time (see Fig. 3). The exceptions were those on BBs and
other treatment groups, for whom there appeared to be some lim-
ited evidence of association with BD outcomes. As before, we
investigated subgroups within AA and BBs. The associations for
both ACE inhibitors and ARBs were the same as for AAs
Fig. 1. First onset of mood disorders, as indicated by receipt of prescriptions or admission to hospital, by therapy class (people without mental illness). This figure
shows cumulative distribution functions for MDD (panel a) and BD (panel b) by therapy class for people without a history of treatment for mental illness (cohort 1).
‘Other Antihypertensives’ were defined on the basis of treatment with a combination of thiazide diuretics, diuretics, BBs, AA and/or CCBs, but not treatment with at
least two of these groups within in the last 3 months of the eligible treatment window.
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combined, and participants who were treated with atenolol and
other BBs also had a reduced risk of being treated for BD. In
contrast, those treated with propranolol had a much higher risk
of being treated for BD at 0–3 months (HR 3.33, 95% CI
1.08–10.27), with the risk falling gradually thereafter. We ran sep-
arate analyses for men (online Supplementary Fig. S7) and women
(online Supplementary Fig. S8) and there was little evidence of
gender differences that could not have occurred by chance.
A slightly more complex pattern was evident in adjusted ana-
lyses for those with a prior history of mood disorder (cohort 2;
online Supplementary Fig. S9). Most antihypertensive classes
were initially associated with a small reduction in risk during
the first 3 months. However, this tended to change over time
and after a year was associated with increased risk of BD. The
exceptions to this were the ‘other antihypertensive’ group and
BBs, which were both associated with increased risk of new-onset
treatment for BD. As above, additional analyses indicated that this
elevated risk for BBs was restricted to propranolol.
Discussion
Overall, our findings do not provide support for the repurposing
of antihypertensive drugs as treatments for depression. Relative to
the comparison group, most classes of antihypertensive were asso-
ciated with small increased risks of being treated for MDD and a
slightly lower risk of being treated for new-onset BD. The main
Fig. 2. HRs for new onset depression, as indicated
by receipt of prescriptions or admission to hospital,
by therapy class (people without mental illness).
This figure shows HRs for new onset depression by
therapy class for people without a history of
treatment for mental illness (Cohort 1).
Adjustment was carried out for hospital treatment
for cardiovascular disease, substance abuse, head
injury, self-harm and pharmaceutical treatment for
other cardiovascular drugs and diabetic drugs.
‘Other Antihypertensives’ were defined on the
basis of treatment with a combination of thiazide
diuretics, diuretics, BBs, AA and/or CCBs, but not
treatment with at least two of these groups within
in the last 3 months of the eligible treatment
window.
Fig. 3. HRs for new onset BD, as indicated by
receipt of prescriptions or admission to hospital,
by therapy class (people without mental illness).
This figure shows HRs for new BD by therapy class
for people without a history of treatment for mental
illness (Cohort 1). Adjustment was carried out for
hospital treatment for cardiovascular disease, sub-
stance abuse, head injury, self-harm and pharma-
ceutical treatment for other cardiovascular drugs
and diabetic drugs. ‘Other Antihypertensives’ were
defined on the basis of treatment with a combin-
ation of thiazide diuretics, diuretics, BBs, AA and/or
CCBs, but not treatment with at least two of these
groups within in the last 3 months of the eligible
treatment window.
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exceptions to this were for patients treated with BBs, which were
associated with increased risk of subsequent treatment for both
MDD and BD (this is perhaps unsurprising given the widespread
use of BBs as anxiolytics).
Our results are consistent with studies suggesting that pro-
pranolol may be associated with increased long-term risk of
mood disorders (Luijendijk & Koolman, 2012; Verbeek et al.,
2011). Additionally, given our study design, our findings are con-
sistent with those of the work of Kessing and colleagues (Kessing
et al., 2019a, 2019b). Relative to untreated comparison group’s,
both Kessing et al. and our study had similar results in that pre-
scriptions for AAs were associated with a small increased risk of
depression (Kessing et al., 2019b) and a reduced risk of BD
(Kessing et al., 2019a).
Our design is an advance on previous work (Boal et al., 2016)
which did not include a control group. Kessing et al. correctly
highlight that people with hypertension have a small increased
risk of future depression. Their solution was to compare periods
where patients had received a cumulative three or more prescrip-
tions of AAs relative to a reference period which included people
who had only one or two prescriptions for AAs. While this
approach might to some extent address the confounding effects
of hypertension, it does also have a potential to add other biases.
The comparison group used by Kessing et al. included people who
only ever received one or two prescriptions of AAs. In our study,
those who received an initial treatment with AAs but then
swapped to other antihypertensives had greatly elevated risk of
depression, suggesting that the control group in the Kessing
et al. study may be confounded by other aspects relating to adher-
ence to medication (Kessing et al., 2019a, 2019b).
Using observational data it is extremely unlikely that any one
study design will address all potential biases, and it is necessary to
compare across studies and designs, a process termed triangula-
tion (Lawlor, Tilling, & Davey Smith, 2016). On balance, it
would appear from the existing literature that AAs are a good can-
didate for repurposing to treat BD. The evidence for repurposing
antihypertensive drugs to treat MDD is weaker. Previously
reported protective associations (Kessing et al., 2019b) and the
negative associations in our study are weak and occur across dif-
ferent classes of medication. The similarity of associations across
multiple classes of medication might reflect non-biological
mechanisms and it is well established that patients who are in
regular contact with their General Practitioners (for example,
for medication reviews or monitoring of blood pressure) are
more likely to have psychological problems identified than
patients with fewer regular consultations (Bushnell, 2004).
Ultimately only a well-designed randomized controlled trial is
likely to resolve these issues but it is unclear at this stage whether
the opportunity costs in carrying out such a study are justified.
Limitations
In 2011, which is within our study period, guidelines on the treat-
ment of hypertension changed and BBs were no longer a preferred
initial therapy for hypertension (National Institute for Health &
Care Excellence (NICE), 2011). As noted above, BBs such as pro-
pranolol are commonly used in primary care settings to treat anx-
iety (Hayes & Schulz, 1987), as well as for thyrotoxicosis, and
angina. It was not possible for us to identify from prescription
records the exact reasons for treatment choices. The observed
increased risk of new-onset MDD in this group might therefore
reflect the exacerbation of an already-established affective disorder.
The comparison groups clearly differ with respect to cardio-
vascular history and, despite the cohorts and comparison groups
being selected on the basis of their mood disorder histories, they
may also differ with respect to subclinical symptoms of anxiety
and depression. However, for cohort 1 these differences were
likely to be small for all antihypertensive classes, except BBs. In
contrast, cohort 2’s risk of mood disorders (relative to their com-
parison group) continued to increase over time. This could reflect
poorer mental health among cohort 2, undiagnosed onset of new
mental illnesses among the comparison group, or residual con-
founding factors. Potentially eligible participants for whom we
could not find matches differed from those analysed in that
they were older and tended to have poorer health.
New-onset BD was primarily identified using PIS records. As
such, it was not possible to distinguish between bipolar depressive
states and hypomanic or manic states based on the data that we
had access to. In addition, given that most cases of BD tend to
have an onset in early adulthood (many years before treatment
for hypertension usually starts), it is not clear that we have accur-
ately captured new-onset BD. It is also possible that some of these
patients may have received treatment for BD earlier in life, during
periods (before 1981 for SMR04 and before 2009 for PIS) for
which data was not available.
Our study design identified people who consistently received
antihypertensive monotherapy in order to investigate possible
protective effects of antihypertensive treatments in the medium-
to long-term. As such, this study was not designed to investigate
immediate side effects of antihypertensive treatments. A patient
who developed depressive symptoms and received treatment for
MDD quickly after their first antihypertensive medication pre-
scription would, by design, be included within cohort
2. However, it is difficult to distinguish such people from those
who were selected into cohort 2 due to having prior mental ill-
ness. Consequently, for cohort 2, which we considered our sec-
ondary analyses, the more interesting aspects of the results are
for periods occurring at least 6 months after the initial period
of eligibility. A patient who changed their antihypertensive treat-
ments in the first 12 months of treatment, perhaps due to side-
effects, would have been included in the ‘other antihypertensive’
group, such that membership of this group may indicate add-
itional health problems beyond hypertension. We also did not
have data on whether or not hypertension was being adequately
controlled by medication. This could potentially confound the
results. Another challenge was the classification of patients treated
with multiple antihypertensive treatments. We used a pragmatic
measure of whether people had received treatment from at least
two antihypertensive classes within the final 3 months of the win-
dow used to define eligibility. In theory, this might include people
on changing prescription regimes. However, the risks of MDD
and BD for people in the polytherapy group were within the
range of most monotherapies, suggesting that this was a reason-
ably robust approach.
Conclusion
Using a comprehensive national-level routine healthcare data
linkage approach, we found little evidence to support the idea
that antihypertensive medications might be usefully repurposed
as treatments for MDD. Tentatively, we conclude that some
classes of antihypertensive – and AAs in particular – may offer
some protection against BD, but this could be due to selection
biases, and will require other study designs to resolve.
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